HR Execs on the Move

ArrePath

www.arrepath.com

 
ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.arrepath.com
  • 303a College Rd E
    Princeton, NJ USA 08540
  • Phone: 609.423.1571

Executives

Name Title Contact Details
Lloyd Payne
Chief Executive Officer Profile

Similar Companies

BiOptix

BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements.

Wheeler Bio

A disruptive new biopharmaceutical CDMO, we are pushing the boundaries of biomanufacturing and solving an outdated industry bottleneck with a unique partnering model. By bringing together biologics drug innovators, discovery CROs, and CDMOs, we are accelerating the translation of therapeutic innovation to clinical impact.

Artemisia BioMedical

Artemisia BioMedical is a Renton, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Threshold Pharmaceuticals

Threshold Pharmaceuticals, Inc. is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Codagenix

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells.